Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNeurology/NeurosurgeryAspirus Arise Acthar Gel Coverage Prior Auth | Ope…
    Ask Trek AI about this page
    CurrentAspirus ArisePolicy N/A

    Repository Corticotropin (Acthar Gel) — Utilization Management

    Customize your policy alerts

    Sign up for all Aspirus Arise policy alerts

    Know when Aspirus Arise releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, coverage criteria, dosing, and non-coverage conditions for Acthar Gel for members of Aspirus Medicare Plans, and directs prescribing by or in consultation with specialists.

    Policy Summary
    PayerAspirus Arise
    PolicyRepository Corticotropin (Acthar Gel) — Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2021
    Last ReviewSep 15, 2025
    Next Review DateSep 15, 2025
    Key ActionObtain prior authorization and document patient age, IM route, dosing, formulation (multidose vial), and neurology consultation or specialist involvement.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Infantile spasmsFDA‑approved covered indication
    Up to 150 U/m2/dayApproved dosing (infantile spasms)

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Prior authAuthorization process
    Multidose vial onlyFormulation restriction
    Multiple listedNot recommended indications

    Coverage Criteria

    Infantile Spasms — Initial Therapy

    Covered when ALL of the following are met:

    Infantile Spasms (FDA-Approved): A) Child is less than 2 years of age; AND B) Acthar is being administered as an intramuscular injection; AND C) Medication is prescribed by a physician who has consulted with or specializes in neurology.Dosing: Approve up to 150 units/m2 by intramuscular injection per day for up to 1 month

    Acthar Gel single-dose prefilled SelfJect injector (subcutaneous) should not be approved for infantile spasms.

    Coverage of Acthar Gel is not recommended for the following conditions: ankylosing spondylitis; dermatomyositis or polymyositis; diabetic nephropathy; glomerular kidney diseases (including nephrotic syndrome, membranous nephropathy, IgA nephropathy, minimal change disease, infection‑related glomerulonephritis, focal segmental glomerulosclerosis, and membranoproliferative glomerulonephritis); gout; juvenile idiopathic arthritis; lupus nephritis; multiple sclerosis, acute exacerbations; ophthalmic conditions (e.g., acute optic neuritis, keratitis, retinal vasculitis); psoriatic arthritis; rheumatoid arthritis; sarcoidosis; and for circumstances not listed in the Recommended Authorization Criteria.

    Use of Acthar Gel for the conditions listed above is not recommended for coverage because clinical guidelines and specialty society recommendations generally do not identify ACTH (repository corticotropin) as a standard therapy for these diseases, and high‑quality evidence supporting its use is lacking. Examples include guideline statements that do not cite ACTH for ankylosing spondylitis, idiopathic inflammatory myopathies, gout, juvenile idiopathic arthritis, psoriatic arthritis, and rheumatoid arthritis; KDIGO and other renal guidelines that do not endorse ACTH for glomerular diseases or lupus nephritis; and limited data for ophthalmic conditions and sarcoidosis, where repository corticotropin is suggested only after failure of recommended therapies. Requests for Acthar for these indications may therefore be denied.

    Coding and Dosing

    Covered HCPCS (example)HCPCS
    J0800Repository corticotropin, porcine, 1 mg (example billing code — policy does not list explicit codes; include common HCPCS used for Acthar)
    Infantile spasms dosing
    IndicationInfantile spasms (FDA‑approved) — patient <2 years of age
    RouteIntramuscular injection (multidose vial required for infantile spasms)
    DoseUp to 150 units/m2 per day (administered as 2 injections of 75 units/m2)
    DurationApprove for up to 1 month; after 2 weeks, dose should be tapered and discontinued over 2 weeks
    Prescriber requirementPrescribed by a physician who has consulted with or specializes in neurology

    Provider Actions and Authorization

    Prior Authorization

    Prior authorization required for Acthar Gel

    Prior authorization is required for Acthar Gel; approval is recommended only when the patient meets the specified authorization criteria (e.g., infantile spasms criteria). Approval requires that Acthar be prescribed by or in consultation with a physician who specializes in the condition being treated. Requests for doses outside the dosing documented in this policy will be reviewed case‑by‑case by a clinician.

    • Prior authorization recommended for prescription benefit coverage of Acthar Gel.
    • Approvals provided only when all applicable Criteria and Dosing are met.
    • Doses outside established dosing will be considered case‑by‑case by a Medical Director or Pharmacist.
    Step Therapy

    Step therapy guidance — reserve repository corticotropin for refractory cases

    No formal step therapy algorithm is specified in this policy. Clinical guidelines (for example, sarcoidosis guidance) recommend reserving repository corticotropin for patients who have failed prior treatments, so consider Acthar only after standard therapies are ineffective or not tolerated.

    Product Definitions

    Acthar Gel SelfJect
    Device descriptionActhar Gel SelfJect: single‑dose prefilled subcutaneous injector for adults
    Available strengthsSingle‑dose 40 unit or 80 unit injector doses only
    Age/indication restrictionIntended for adult subcutaneous use; NOT for treatment of infantile spasms
    Formulation distinctionInfantile spasms must be treated with the multidose vial given intramuscularly; SelfJect is not appropriate

    Background

    Acthar Gel is a repository corticotropin (an ACTH analog) available for intramuscular or subcutaneous administration. It is indicated for infantile spasms (treatment in infants) and has been used in other settings such as multiple sclerosis exacerbations, but guideline support and evidence vary by indication. For the treatment of infantile spasms, the policy requires use of the multidose vial given by intramuscular injection; the single‑dose prefilled SelfJect subcutaneous injector is intended for adult doses and should not be used for infantile spasms. Dosing guidance for infantile spasms supports approval up to 150 units/m2/day IM for up to 1 month when criteria are met.

    Policy Summary
    PayerAspirus Arise
    PolicyRepository Corticotropin (Acthar Gel) — Utilization Management
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJan 1, 2021
    Last ReviewSep 15, 2025
    Next Review DateSep 15, 2025
    Key ActionObtain prior authorization and document patient age, IM route, dosing, formulation (multidose vial), and neurology consultation or specialist involvement.
    SourceLink
    On This Page
    Coverage CriteriaCoding and DosingProvider Actions and AuthorizationProduct DefinitionsBackground
    • Policy does not define a stepwise prior authorization sequence.
    • Guidelines (European Respiratory Society for sarcoidosis) recommend reserving repository corticotropin for patients who have failed prior treatments (e.g., steroids, antimetabolites).
    Documentation Required

    Required documentation to support authorization

    Prescriber must document key clinical details supporting use: patient age, route of administration, prescriber specialty/consultation, dosing, and formulation.

    • Document that the child is less than 2 years of age for infantile spasms.
    • Document intramuscular route of administration for infantile spasms and that the multidose vial (not SelfJect) is being used.
    • Record that the medication is prescribed by or in consultation with a physician who specializes in neurology, and record the dosing (up to 150 units/m2/day for up to 1 month).
    Denial Risk

    Denial triggers — indications not recommended for approval

    Requests for Acthar for indications listed under 'Conditions Not Recommended for Approval' or for circumstances not included in the Recommended Authorization Criteria are not recommended for coverage and may be denied.

    • Do not submit requests for conditions specifically listed as not recommended (e.g., ankylosing spondylitis, lupus nephritis, multiple sclerosis acute exacerbations, sarcoidosis, psoriatic arthritis, rheumatoid arthritis, ophthalmic conditions, and various glomerular kidney diseases).
    • Requests for circumstances not listed in the Recommended Authorization Criteria may be denied.